2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Flammable

Harmful

Danger

H223Flammable aerosol

H229Pressurised container: may burst if heated

H312Harmful in contact with skin

H332Harmful if inhaled

H319Causes serious eye irritation

Identifiers

IUPAC Name

(2R,4R)-1-[(2S)-5-(diaminomethylideneamino)-2-[(3-methyl-1,2,3,4-tetrahydroquinolin-8-yl)sulfonylamino]pentanoyl]-4-methylpiperidine-2-carboxylic acid;hydrate

InChIKey

AIEZTKLTLCMZIA-CZSXTPSTSA-N

SMILES

C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NCC(C3)C.O

Synonyms (21)

Argatroban (USP)
Argatra
Argatroban
Argatroban Injection
Argatroban hydrate
Argatroban hydrate (JP18)
Argatroban monohydrate
Exembol
Novastan (TN)
Slonnon

Sourcing Argatroban monohydrate?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request Supplier? List your product for this CAS

Argatroban monohydrate

Related Compounds

Related Reading

Safety Reference